about the author

Brittany Meiling

editors@endpointsnews.com
Brittany Meiling on LinkedIn

author articles

Pfiz­er’s lat­est copy­cat could put the squeeze on Roche — again

8 years ago
R&D
Pharma

When VCs hand out mega-rounds to Vir and Gos­samer, are they bet­ting on the jock­ey or the horse?

8 years ago
Financing
Startups

Pan­cre­at­ic can­cer com­bo sees high sur­vival rates in Chemo­Cen­tryx PhIb da­ta

8 years ago
R&D

FDA slaps down Brae­burn on opi­oid ad­dic­tion drug, putting In­di­v­ior and Alk­er­mes in strong po­si­tion

8 years ago
Pharma

Gov­ern­ment shut­down to end - at least tem­porar­i­ly - as Dems take Mc­Connell at his word

8 years ago
Pharma

What are the top 10 cor­po­rate VCs in bio­phar­ma to­day? And what do they want to fund — or steer clear of?

8 years ago
Financing

Drug­mak­ers take to Japan: 3 new drug ap­provals won by As­traZeneca, Mer­ck, and EA Phar­ma

8 years ago
Pharma

In­sid­er trad­ing scam spurred by $11.2B Gilead deal earns a stretch in prison

8 years ago
Pharma

Where the mon­ey is: Top 100 VCs in­vest­ing in US biotechs dur­ing 2017

8 years ago
Financing
Special

Mer­ck KGaA taps UK can­cer re­search or­ga­ni­za­tions to feed pipeline

8 years ago
R&D
Pharma

AveX­is wants $400M more for promis­ing SMA gene ther­a­py; Shang­Phar­ma part­ners with Ic­ahn School of Med­i­cine at Mount ...

8 years ago
News Briefing

Ger­man drug­mak­er files $21.6M IPO for skin can­cer drug

8 years ago
Financing

HHS pick Azar draws the line on drug price ne­go­ti­a­tions at Medicare; As­traZeneca inks on­col­o­gy re­search deal at JPM

8 years ago
News Briefing

The Cam­bridge siren call: Philips NV mov­ing HQ to mega-project Cam­bridge Cross­ing

8 years ago
Pharma

Brae­burn bags $110M in launch cash as PDU­FA date rolls up; En­do sub­poe­naed for doc­u­ments on opi­oid painkillers

8 years ago
News Briefing

Teva's board slash­es its own com­pen­sa­tion fol­low­ing mas­sive re­struc­tur­ing

8 years ago
R&D

Mod­er­na ex­pands pipeline to in­clude liv­er dis­ease pro­grams; Im­pe­r­i­al re­searchers team up with Hep­tares on ...

8 years ago
News Briefing

Blue­bird hopes for 3 drug ap­provals by 2019, in­clud­ing CAR-T and gene ther­a­pies

8 years ago
Cell/Gene Tx

Pfiz­er inks deal with start­up Adap­syn to search mi­crobes for nov­el com­pounds

8 years ago
Startups
AI

On a mis­sion to save Te­va from crip­pling debt, Schultz stands by cost-cut­ting mea­sures, scru­ti­nizes per prod­uct ...

8 years ago
R&D
Pharma

Af­ter bumpy 2017, Cel­gene CEO says tak­ing risk is the on­ly way for­ward

8 years ago
Pharma

Te­va inks $200M glob­al li­cens­ing deal with mi­graine ri­val Alder

8 years ago
R&D
Pharma

De­vel­op­ing a Sanofi cast-off, Im­pact Bio­med­i­cines now sub­ject of $7B Cel­gene ac­qui­si­tion deal

8 years ago
Deals

J&J does Alzheimer's gene ther­a­py deal, along with 14 oth­er new col­lab­o­ra­tions

8 years ago
Cell/Gene Tx
First page Previous page 10111213141516 Next page Last page
A service from the Financial Times